​

Ginkgo Bioworks (DNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DNA Stock Forecast

Ginkgo Bioworks (DNA) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $7.84, with a high of $12.00 and a low of $4.35. This represents a 15.29% increase from the last price of $6.80.

- $3 $6 $9 $12 $15 High: $12 Avg: $7.84 Low: $4.35 Last Closed Price: $6.8

DNA Stock Rating

Ginkgo Bioworks stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (45.45%), 2 Hold (18.18%), 4 Sell (36.36%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 4 2 5 Strong Sell Sell Hold Buy Strong Buy

DNA Price Target Upside V Benchmarks

TypeNameUpside
StockGinkgo Bioworks15.29%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$9.00
Last Closing Price$6.80$6.80$6.80
Upside/Downside--32.35%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-1-124
Feb, 26-1-124
Jan, 26-1-124
Dec, 25-1-124
Nov, 25-1-124
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 25, 2025BTIG$9.00$12.05-25.31%32.35%
Aug 23, 2024Mark MassaroBTIG$7.00$8.30-15.66%2.94%
Nov 29, 2022Berenberg Bank$6.00$1.84226.09%-11.76%
Aug 16, 2022BTIG$6.00$3.7460.43%-11.76%
Jun 16, 2022Jefferies$4.35$2.5967.95%-36.03%
Mar 03, 2022Steven MahCowen & Co.$12.00$3.86210.88%76.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 25, 2025BTIGSellSellhold
Aug 08, 2025Cowen & Co.BuyBuyhold
Sep 17, 2024Cowen & Co.BuyBuyhold
Aug 23, 2024BTIGSellSellhold
Jun 26, 2024BTIGSellSellhold
May 15, 2024BTIGBuySelldowngrade
May 10, 2024William BlairUnderperformdowngrade
Aug 16, 2022Raymond JamesOutperformOutperformhold
Aug 16, 2022BTIGBuyBuyhold
Aug 16, 2022CLSASelldowngrade

Financial Forecast

EPS Forecast

$-60 $-48 $-36 $-24 $-12 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-53.83$-50.15$-18.37$-10.54$-5.64---
Avg Forecast$-7.90$-55.63$-17.60$-10.08$-5.81$-3.36$-4.14$-3.33
High Forecast$-7.38$-53.75$-16.80$-9.59$-4.33$-2.52$-3.94$-3.17
Low Forecast$-8.35$-57.89$-18.80$-10.65$-7.28$-4.25$-4.37$-3.52
Surprise %581.39%-9.85%4.38%4.56%-2.93%---

Revenue Forecast

$150M $220M $290M $360M $430M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$313.84M$477.71M$251.46M$227.04M$170.16M---
Avg Forecast$251.52M$471.16M$258.72M$227.75M$203.81M$246.09M$332.30M$396.40M
High Forecast$262.48M$485.92M$259.77M$227.86M$205.13M$246.09M$346.64M$413.50M
Low Forecast$238.79M$458.90M$257.68M$227.63M$202.49M$246.09M$319.94M$381.65M
Surprise %24.78%1.39%-2.81%-0.31%-16.51%---

Net Income Forecast

$-3B $-2B $-2B $-1B $-600M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.83B$-2.10B$-892.87M$-547.03M$-312.76M---
Avg Forecast$-384.02M$-2.70B$-892.87M$-491.88M$-308.02M$-188.72M$-201.25M$-161.87M
High Forecast$-358.76M$-2.61B$-816.66M$-466.29M$-210.29M$-122.50M$-191.51M$-154.04M
Low Forecast$-405.79M$-2.81B$-913.88M$-517.47M$-354.09M$-206.59M$-212.53M$-170.95M
Surprise %376.55%-22.16%-11.21%1.54%---

DNA Forecast FAQ

Is Ginkgo Bioworks stock a buy?

Ginkgo Bioworks stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Ginkgo Bioworks is a favorable investment for most analysts.

What is Ginkgo Bioworks's price target?

Ginkgo Bioworks's price target, set by 11 Wall Street analysts, averages $7.84 over the next 12 months. The price target range spans from $4.35 at the low end to $12 at the high end, suggesting a potential 15.29% change from the previous closing price of $6.8.

How does Ginkgo Bioworks stock forecast compare to its benchmarks?

Ginkgo Bioworks's stock forecast shows a 15.29% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ginkgo Bioworks over the past three months?

  • March 2026: 0% Strong Buy, 25.00% Buy, 0% Hold, 25.00% Sell, 50.00% Strong Sell.
  • February 2026: 0% Strong Buy, 25.00% Buy, 0% Hold, 25.00% Sell, 50.00% Strong Sell.
  • January 2026: 0% Strong Buy, 25.00% Buy, 0% Hold, 25.00% Sell, 50.00% Strong Sell.

What is Ginkgo Bioworks’s EPS forecast?

Ginkgo Bioworks's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.36, marking a -40.43% decrease from the reported $-5.64 in 2025. Estimates for the following years are $-4.14 in 2027, and $-3.33 in 2028.

What is Ginkgo Bioworks’s revenue forecast?

Ginkgo Bioworks's average annual revenue forecast for its fiscal year ending in December 2026 is $246.09M, reflecting a 44.63% increase from the reported $170.16M in 2025. The forecast for 2027 is $332.3M, and $396.4M for 2028.

What is Ginkgo Bioworks’s net income forecast?

Ginkgo Bioworks's net income forecast for the fiscal year ending in December 2026 stands at $-189M, representing a -39.66% decrease from the reported $-313M in 2025. Projections indicate $-201M in 2027, and $-162M in 2028.